CoChat
Sign Up
Cited by 116

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells*

Stuart, Scott A., Houel, Stephane, Lee, Thomas, Wang, Nan, Old, William M., Ahn, Natalie G.·2015·Molecular & Cellular Proteomics
DOI 10.1074/mcp.m114.047233
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/mcp.m114.047233

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Phosphorylation at corresponding sites in SNX1, SNX3, SNX12, and SNX17 has been reported in various cancer types.

    “phosphorylation at corresponding sites in SNX1, SNX3, SNX12, and SNX17 has been reported in various cancer types (47, 48, 49, 50, 51, 52)”

    From Phosphorylation of SNX17 impedes activation of Retriever-mediated sorting (2025) · cites this paper as [48]

    The results section identifies SNX13 as a phosphosite-bearing target in melanoma cells, but it does not establish phosphorylation at corresponding sites in SNX1, SNX3, SNX12, or SNX17. Searches for those proteins and sorting-nexin phosphosites found no passage in our copy reporting the claimed sites across various cancer types. (LLM, conf=0.72)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 65

  1. Matallanas, 2011, Raf family kinases: Old dogs have learned new tricks, Genes Cancer, 2, 232, 10.1177/1947601911407323 · DOI
  2. Hindley, 2002, Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases, J. Cell Sci, 115, 1575, 10.1242/jcs.115.8.1575 · DOI
  3. Roskoski, 2012, MEK1/2 dual-specificity protein kinases: structure and regulation, Biochem. Biophys. Res. Commun, 417, 5, 10.1016/j.bbrc.2011.11.145 · DOI
  4. Yoon, 2006, The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions, Growth Factors, 24, 21, 10.1080/02699050500284218 · DOI
  5. Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 · DOI · Paper page
  6. Sullivan, 2013, The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be, Clin. Cancer Res, 19, 5283, 10.1158/1078-0432.CCR-13-2151 · DOI
  7. Van Raamsdonk, 2009, Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi, Nature, 457, 599, 10.1038/nature07586 · DOI
  8. Van Raamsdonk, 2010, Mutations in GNA11 in uveal melanoma, N. Engl. J. Med, 363, 2191, 10.1056/NEJMoa1000584 · DOI
  9. Andersen, 1993, Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines, Nat. Genet, 3, 118, 10.1038/ng0293-118 · DOI
  10. Hauschild, 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 380, 358, 10.1016/S0140-6736(12)60868-X · DOI
  11. Flaherty, 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma, N. Engl. J. Med, 367, 107, 10.1056/NEJMoa1203421 · DOI
  12. Larkin, 2014, Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma, N. Engl. J. Med, 371, 1867, 10.1056/NEJMoa1408868 · DOI
  13. Carvajal, 2014, Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial, Jama, 311, 2397, 10.1001/jama.2014.6096 · DOI
  14. Robert, 2014, Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib, N. Engl. J. Med
  15. Long, 2014, Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma, N. Engl. J. Med, 371, 1877, 10.1056/NEJMoa1406037 · DOI
  16. Bollag, 2010, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma, Nature, 467, 596, 10.1038/nature09454 · DOI
  17. Hartsough, 2014, Resistance to RAF inhibitors revisited, J. Invest. Dermatol, 134, 319, 10.1038/jid.2013.358 · DOI
  18. Lewis, 2000, Identification of Novel MAP Kinase Pathway Signaling Targets by Functional Proteomics and Mass Spectrometry, Mol. Cell, 6, 1343, 10.1016/S1097-2765(00)00132-5 · DOI
  19. Kosako, 2009, Phosphoproteomics reveals new ERK MAP kinase targets and links ERK to nucleoporin-mediated nuclear transport, Nat. Struct. Mol. Biol, 16, 1026, 10.1038/nsmb.1656 · DOI
  20. Eblen, 2003, Identification of novel ERK2 substrates through use of an engineered kinase and ATP analogs, J. Biol. Chem, 278, 14926, 10.1074/jbc.M300485200 · DOI
  21. Carlson, 2011, Large-scale discovery of ERK2 substrates identifies ERK-mediated transcriptional regulation by ETV3, Sci. Signal, 4, rs11, 10.1126/scisignal.2002010 · DOI
  22. Old, 2009, Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma, Mol. Cell, 34, 115, 10.1016/j.molcel.2009.03.007 · DOI
  23. Pan, 2009, Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics, Mol. Cell. Proteomics, 8, 2796, 10.1074/mcp.M900285-MCP200 · DOI
  24. Galan, 2014, Phosphoproteomic analysis identifies the tumor suppressor PDCD4 as a RSK substrate negatively regulated by 14–3-3, Proc. Natl. Acad. Sci. U. S. A, 111, E2918, 10.1073/pnas.1405601111 · DOI · Paper page
  25. Courcelles, 2013, Phosphoproteome dynamics reveal novel ERK1/2 MAP kinase substrates with broad spectrum of functions, Mol. Syst. Biol, 9, 669, 10.1038/msb.2013.25 · DOI
  26. Parker, 2014, Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition, Mol. Cancer Ther, 13, 1894, 10.1158/1535-7163.MCT-13-0938 · DOI
  27. Cox, 2008, MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification, Nat. Biotechnol, 26, 1367, 10.1038/nbt.1511 · DOI · Paper page
  28. Vizcaíno, 2014, ProteomeXchange provides globally coordinated proteomics data submission and dissemination, Nat. Biotechnol, 32, 223, 10.1038/nbt.2839 · DOI
  29. Ong, 2006, A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC), Nat. Protoc, 1, 2650, 10.1038/nprot.2006.427 · DOI
  30. Alpert, 2008, HPLC 2008 Conference, Baltimore, MD
  31. Boichenko, 2013, Multidimensional separation of tryptic peptides from human serum proteins using reversed-phase, strong cation exchange, weak anion exchange, and fused-core fluorinated stationary phases, J. Sep. Sci, 36, 3463, 10.1002/jssc.201300750 · DOI
  32. Olsen, 2006, Global, in vivo, and site-specific phosphorylation dynamics in signaling networks, Cell, 127, 635, 10.1016/j.cell.2006.09.026 · DOI
  33. Basbous, 2007, Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer, Mol. Cell. Biol, 27, 3936, 10.1128/MCB.01776-06 · DOI
  34. Snel, 2000, STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene, Nucleic Acids Res, 28, 3442, 10.1093/nar/28.18.3442 · DOI
  35. Von Mering, 2007, STRING 7–recent developments in the integration and prediction of protein interactions, Nucleic Acids Res, 35, D358, 10.1093/nar/gkl825 · DOI
  36. Gille, 1995, ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation, EMBO J, 14, 951, 10.1002/j.1460-2075.1995.tb07076.x · DOI
  37. Pulverer, 1991, Phosphorylation of c-jun mediated by MAP kinases, Nature, 353, 670, 10.1038/353670a0 · DOI
  38. Young, 2002, Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently, Mol. Cell. Biol, 22, 587, 10.1128/MCB.22.2.587-598.2002 · DOI
  39. Alvarez, 1991, Pro-Leu-Ser/Thr-Pro is a consensus primary sequence for substrate protein phosphorylation. Characterization of the phosphorylation of c-myc and c-jun proteins by an epidermal growth factor receptor threonine 669 protein kinase, J. Biol. Chem, 266, 15277, 10.1016/S0021-9258(18)98613-8 · DOI
  40. Mi, 2013, Large-scale gene function analysis with the PANTHER classification system, Nat. Protoc, 8, 1551, 10.1038/nprot.2013.092 · DOI
  41. Benedit, 2001, PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks, Oncogene, 20, 1455, 10.1038/sj.onc.1204233 · DOI
  42. Yoshida, 2000, ATF6 activated by proteolysis binds in the presence of NF-Y (CBF) directly to the cis-acting element responsible for the mammalian unfolded protein response, Mol. Cell. Biol, 20, 6755, 10.1128/MCB.20.18.6755-6767.2000 · DOI · Paper page
  43. Massari, 1996, The AD1 transactivation domain of E2A contains a highly conserved helix which is required for its activity in both Saccharomyces cerevisiae and mammalian cells, Mol. Cell. Biol, 16, 121, 10.1128/MCB.16.1.121 · DOI
  44. Cowell, 1994, Transcriptional repression by the human bZIP factor E4BP4: definition of a minimal repression domain, Nucleic Acids Res, 22, 59, 10.1093/nar/22.1.59 · DOI
  45. Sharp, 2004, LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription, Proc. Natl. Acad. Sci. U. S. A, 101, 16531, 10.1073/pnas.0407123101 · DOI
  46. Hornbeck, 2012, PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse, Nucleic Acids Res, 40, D261, 10.1093/nar/gkr1122 · DOI
  47. Dougherty, 2005, Regulation of Raf-1 by direct feedback phosphorylation, Mol. Cell, 17, 215, 10.1016/j.molcel.2004.11.055 · DOI
  48. Tigno-Aranjuez, 2010, Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses, Genes Dev, 24, 2666, 10.1101/gad.1964410 · DOI
  49. Navas, 1999, RIP2 is a Raf1-activated mitogen-activated protein kinase kinase, J. Biol. Chem, 274, 33684, 10.1074/jbc.274.47.33684 · DOI
  50. Gan, 2008, A comparative study of electrostatic repulsion-hydrophilic interaction chromatography (ERLIC) versus SCX-IMAC-based methods for phosphopeptide isolation/enrichment, J. Proteome Res, 7, 4869, 10.1021/pr800473j · DOI
  51. Zarei, 2011, Comparison of ERLIC-TiO2, HILIC-TiO2, and SCX-TiO2 for global phosphoproteomics approaches, J. Proteome Res, 10, 3474, 10.1021/pr200092z · DOI
  52. Zarei, 2012, Combinatorial use of electrostatic repulsion-hydrophilic interaction chromatography (ERLIC) and strong cation exchange (SCX) chromatography for in-depth phosphoproteome analysis, J. Proteome Res, 11, 4269, 10.1021/pr300375d · DOI
  53. Zarei, 2013, Rapid combinatorial ERLIC-SCX solid-phase extraction for in-depth phosphoproteome analysis, J. Proteome Res, 12, 5989, 10.1021/pr4007969 · DOI
  54. Fernández, 2011, PTOV1 is overexpressed in human high-grade malignant tumors, Virchows Arch, 458, 323, 10.1007/s00428-010-1018-1 · DOI
  55. Wang, 2004, A novel human homologue of Drosophila polycomblike gene is up-regulated in multiple cancers, Gene, 343, 69, 10.1016/j.gene.2004.09.006 · DOI
  56. Jiang, 2007, Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis, Cancer Res, 67, 9750, 10.1158/0008-5472.CAN-07-2047 · DOI
  57. Jiang, 2008, Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress, Cancer Res, 68, 6708, 10.1158/0008-5472.CAN-08-0349 · DOI
  58. Wang, 2009, The CREB coactivator CRTC2 links hepatic ER stress and fasting gluconeogenesis, Nature, 460, 534, 10.1038/nature08111 · DOI
  59. Hömig-Hölzel, 2011, Antagonistic TSC22D1 variants control BRAF(E600)-induced senescence, EMBO J, 30, 1753, 10.1038/emboj.2011.95 · DOI
  60. Haass, 2008, The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel, Clin. Cancer Res, 14, 230, 10.1158/1078-0432.CCR-07-1440 · DOI
  61. Collisson, 2003, Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade, Cancer Res, 63, 5669
  62. Wang, 2007, Clinical experience of MEK inhibitors in cancer therapy, Biochim. Biophys. Acta, 1773, 1248, 10.1016/j.bbamcr.2006.11.009 · DOI
  63. Beltrao, 2013, Evolution and functional cross-talk of protein post-translational modifications, Mol. Syst. Biol, 9, 714, 10.1002/msb.201304521 · DOI
  64. Beltrao, 2012, Systematic functional prioritization of protein posttranslational modifications, Cell, 150, 413, 10.1016/j.cell.2012.05.036 · DOI
  65. Micallef, 2014, eulerAPE: drawing area-proportional 3-Venn diagrams using ellipses, PLoS One, 9, e101717, 10.1371/journal.pone.0101717 · DOI

Cited by

Sorted by citations

Metadata

Authors
Stuart, S. A., Houel, S., Lee, T., Wang, N., Old, W. M., & Ahn, N. G.
Venue
Molecular & Cellular Proteomics
Publisher
Elsevier BV
Published
2015-06
Volume
14
Issue
6
Pages
1599-1615
ISSN
1535-9476
DOI
10.1074/mcp.m114.047233
Cited by
116
References
8
Language
en
Licence
Funders
National Institutes of Health (1F32CA154052-01, R01 CA118972, R21 CA175448)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review